

# Izabela Kuprys-Lipinska

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10422321/publications.pdf>

Version: 2024-02-01

23  
papers

180  
citations

1163117

8  
h-index

1125743

13  
g-index

25  
all docs

25  
docs citations

25  
times ranked

341  
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of Transcript Variants of PTGS1 and PTGS2 Genes among Patients with Chronic Rhinosinusitis with Nasal Polyps. <i>Diagnostics</i> , 2021, 11, 135.	2.6	5
2	Expression of cPLA <sub>2</sub> <sup>γ</sup> mRNA and protein differs the response of PBMC from severe and non-severe asthmatics to bacterial lipopolysaccharide and house dust mite allergen. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842199095.	2.1	2
3	Biomarkers for predicting response to aspirin-exacerbated respiratory disease. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1046-1056.	2.9	9
4	New approach to intermittent and mild asthma therapy: evolution or revolution in the GINA guidelines?. <i>Clinical and Translational Allergy</i> , 2020, 10, 19.	3.2	13
5	Artificial neural network identifies nonsteroidal anti-inflammatory drugs exacerbated respiratory disease (N <sup>2</sup> ERD) cohort. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1649-1658.	5.7	7
6	The effect of levocetirizine and montelukast on clinical symptoms, serum level and skin expression of COX-1 and COX-2 enzymes in patients suffering from chronic autoimmune urticaria – a pilot study. <i>Postepy Dermatologii i Alergologii</i> , 2020, 37, 73-80.	0.9	2
7	Polish Society of Allergology statement on the diagnosis and treatment of severe, difficult-to-control bronchial asthma. <i>Postepy Dermatologii i Alergologii</i> , 2019, 36, 147-157.	0.9	3
8	Sputum biomarkers during aspirin desensitization in nonsteroidal anti-inflammatory drugs exacerbated respiratory disease. <i>Respiratory Medicine</i> , 2019, 152, 51-59.	2.9	9
9	Omalizumab therapy in a patient with severe asthma and co-existing chronic obstructive pulmonary disease. <i>Postepy Dermatologii i Alergologii</i> , 2019, 36, 239-241.	0.9	4
10	Prevalence, risk factors and underdiagnosis of asthma in the general population aged over 60 years. <i>Postepy Dermatologii i Alergologii</i> , 2019, 36, 86-91.	0.9	7
11	The position paper of the Polish Society of Allergology on climate changes, natural disasters and allergy and asthma. <i>Postepy Dermatologii i Alergologii</i> , 2018, 35, 552-562.	0.9	3
12	Effectiveness of the Polish program for the treatment of severe allergic asthma with omalizumab: a single-center experience. <i>BMC Pulmonary Medicine</i> , 2016, 16, 61.	2.0	12
13	Effectiveness and adverse events of plasmapheresis and immunoglobulin G infusion in patient with resistant chronic urticaria and angioedema – a case report. <i>Clinical and Translational Allergy</i> , 2015, 5, P8.	3.2	1
14	The whole - genome expression analysis of peripheral blood mononuclear cells from aspirin sensitive asthmatics versus aspirin tolerant patients and healthy donors after in vitro aspirin challenge. <i>Respiratory Research</i> , 2015, 16, 147.	3.6	4
15	Effectiveness of omalizumab in an asthmatic patient with severe airway and blood eosinophilia. <i>Postepy Dermatologii i Alergologii</i> , 2015, 6, 478-479.	0.9	1
16	The prevalence of asthma work relatedness: Preliminary data. <i>International Journal of Occupational Medicine and Environmental Health</i> , 2015, 28, 1025-1029.	1.3	3
17	Loss of asthma control after cessation of omalizumab treatment: real life data. <i>Postepy Dermatologii i Alergologii</i> , 2014, 1, 1-5.	0.9	35
18	The Step Further to Understand the Role of Cytosolic Phospholipase A <sub>2</sub> α and Group X Secretory Phospholipase A <sub>2</sub> in Allergic Inflammation: Pilot Study. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	15

#	ARTICLE	IF	CITATIONS
19	Effectiveness of omalizumab in a patient with a life-threatening episode of bronchospasm and larynx angioedema after exposure to house dust. <i>Postepy Dermatologii I Alergologii</i> , 2014, 1, 39-44.	0.9	7
20	Omalizumab in pregnant women treated due to severe asthma: two of good outcomes of pregnancies. <i>Postepy Dermatologii I Alergologii</i> , 2014, 2, 104-107.	0.9	13
21	Exacerbating Factors Induce Different Gene Expression Profiles in Peripheral Blood Mononuclear Cells from Asthmatics, Patients with Chronic Obstructive Pulmonary Disease and Healthy Subjects. <i>International Archives of Allergy and Immunology</i> , 2014, 165, 229-243.	2.1	13
22	Good outcomes of pregnancy in two cases of women treated with omalizumab due to the severe asthma. <i>Clinical and Translational Allergy</i> , 2013, 3, P25.	3.2	0
23	Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 $\hat{1}/4$ g administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 $\hat{1}/4$ g dry powder inhaler twice daily in patients with moderate asthma. <i>Pneumonologia I Alergologia Polska</i> , 2013, 81, 527-36.	0.6	0